Results 151 to 160 of about 621,791 (286)

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma

open access: yesBritish Journal of Haematology, EarlyView.
In patients with lenalidomide‐refractory multiple myeloma from the BOSTON trial subgroup analysis,1 selinexor (SEL) dose reduction versus full dosing substantially improved efficacy outcomes, including higher overall response rate (74.3% vs. 55.6%), deeper responses (≥ very good partial response: 48.6% vs.
Muhamed Baljevic
wiley   +1 more source

Long‐term oncological outcomes from a prospective cohort of patients with localised prostate cancer

open access: yesBJU International, EarlyView.
Objectives To report long‐term oncological outcomes for men with clinically localised prostate cancer (PCa) treated with contemporary modalities in a population‐based United States cohort. Patients and Methods The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study prospectively enrolled men with clinically localised PCa from ...
Avi S. Baskin   +17 more
wiley   +1 more source

Distinctly altered TRPC3 and TRPC6 expression patterns in human Alzheimer's disease cortex and hippocampus

open access: yesBrain Pathology, EarlyView.
Divergent remodeling of TRPC channels occurs in Alzheimer's disease, with TRPC3 increased in neurons and reactive astrocytes and TRPC6 reduced in pyramidal neurons. These alterations may contribute to calcium dysregulation, neuroinflammation, and synaptic dysfunction during AD progression.
Xingyong Chen   +8 more
wiley   +1 more source

Brain metastasis‐associated fibroblasts shape the tumour microenvironment to enhance cancer cell invasion

open access: yesBrain Pathology, EarlyView.
Brain metastasis‐associated fibroblasts are active stromal components of the metastatic niche characterised by extracellular matrix remodelling and production of pro‐migratory mediators. They promote monocyte and cancer cell migration and enhance cancer cell invasion while having no growth‐promoting effect on cancer cells.
Barbora Výmolová   +19 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

The Synthesis of Natural Tn Antigen Carbohydrate Vaccines

open access: yes
The Synthesis of Natural Tn Antigen Carbohydrate Vaccines Aiyireti (Dina) Dilinaer, Michael R. Reynolds, S. Iraj Sadraei, John F. Trant The immune system plays an important role in defending the human body against diseases and invasion of pathogens. When
Reynolds, Michael R.   +3 more
core   +1 more source

Combining TAG‐72CAR with anti‐MUC16CAR improves the potency of ovarian cancer treatment

open access: yesThe FEBS Journal, EarlyView.
Tz‐KBBCAR, a combinatorial CAR targeting MUC16 and TAG‐72, enhances the precision of ovarian cancer immunotherapy. By requiring both tumour antigens for full activation, Tz‐KBBCAR was designed to eliminate MUC16+/TAG‐72+ cancer cells, while sparing MUC16+/TAG‐72‐ healthy cells.
Alicia Villatoro   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy